Evotec (NASDAQ:EVO) announced today that it will receive a $10 million milestone payment from Bristol Myers Squibb (NYSE:BMY) following the start of a Phase 1 clinical trial for BMS-986506.
The investigational agent, a Cereblon E3 Ligase Modulator (CELMoD), is being evaluated for the treatment of patients with advanced clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer.
The initiation of this trial represents a significant validation of the long-standing strategic partnership between the two companies, which focuses on the discovery and development of next-generation protein degradation therapies.
BMS-986506 was identified and developed using Evotec’s proprietary PanOmics and PanHunter platforms, which utilize high-throughput multi-omics data and advanced analytics to identify high-value disease targets that were previously considered "undruggable."
This milestone is part of a broader collaboration that has already yielded several clinical candidates across oncology and neurodegeneration.
By leveraging the CELMoD platform, the partnership aims to develop oral small molecules that can trigger the degradation of specific proteins driving tumor growth.
For renal cell carcinoma patients who have exhausted standard-of-care options, BMS-986506 offers a novel mechanism of action that could potentially overcome existing resistance patterns.